All In Biotech

Investigational drug · Phase 3

Olatorepatide

Also called: HS-20094

Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

8

6 still active

All registered trials

4

Any phase or sponsor naming "Olatorepatide"

First trial start

2024

Feb 6, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Olatorepatide", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Type 2 Diabetes
  • Overweight or Obesity
  • Overweight or Obesity Without Diabetes
  • Hidradenitis Suppurativa
  • Overweight
  • Obesity

Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Hidradenitis suppurativa · Cardiovascular and metabolic · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "Olatorepatide" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Type 2 Diabetes

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • ZenagamtidePhase 39 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • CagriSemaCagrilintide B and Semaglutide IPhase 36 trials

    Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension

  • HDM1005Phase 35 trials

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Obstructive Sleep Apnea (OSA) and Obesity, Obesity, Type 2 Diabetes

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.